Cargando…
The Health Impact Fund: making the case for engagement with pharmaceutical laboratories in Brazil, Russia, India, and China
Despite progress in global health, the general disease burden still disproportionately falls on low- and middle-income countries. The health needs of these countries’ populations are unmet because there is a shortage in drug research and development, as well as a lack of access to essential drugs. T...
Autores principales: | Lee, Vivian Chia-Jou, Yao, Jacqueline, Zhang, William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419667/ https://www.ncbi.nlm.nih.gov/pubmed/34488801 http://dx.doi.org/10.1186/s12992-021-00744-x |
Ejemplares similares
-
Public funding and private investment for R&D: a survey in China’s pharmaceutical industry
por: Qiu, Lan, et al.
Publicado: (2014) -
Pharmaceutical Policy Part 2 Pharmaceutical engagement and policy development: a framework for influence
por: Morrow, Norman C
Publicado: (2015) -
The roles and training of primary care doctors: China, India, Brazil and South Africa
por: Mash, Robert, et al.
Publicado: (2015) -
Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
por: Richeldi, Luca, et al.
Publicado: (2015) -
Compound asset sharing initiatives between pharmaceutical companies, funding bodies, and academia: Learnings and successes
por: Hayes, Ann G., et al.
Publicado: (2019)